TY - JOUR
T1 - Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review
AU - Toy, Mehlika
AU - Onder, FO
AU - Wormann, T
AU - Bozdayi, AM
AU - Schalm, Solko
AU - Borsboom, Gerard
AU - van Rosmalen, Joost
AU - Richardus, Jan hendrik
AU - Yurdaydin, C
PY - 2011
Y1 - 2011
N2 - Background: To provide a clear picture of the current hepatitis B situation, the authors performed a systematic review to estimate the age-and region-specific prevalence of chronic hepatitis B (CHB) in Turkey. Methods: A total of 339 studies with original data on the prevalence of hepatitis B surface antigen (HBsAg) in Turkey and published between 1999 and 2009 were identified through a search of electronic databases, by reviewing citations, and by writing to authors. After a critical assessment, the authors included 129 studies, divided into categories: 'age-specific'; 'region-specific'; and 'specific population group'. To account for the differences among the studies, a generalized linear mixed model was used to estimate the overall prevalence across all age groups and regions. For specific population groups, the authors calculated the weighted mean prevalence. Results: The estimated overall population prevalence was 4.57, 95% confidence interval (CI): 3.58, 5.76, and the estimated total number of CHB cases was about 3.3 million. The outcomes of the age-specific groups varied from 2.84, (95% CI: 2.60, 3.10) for the 0-14-yearolds to 6.36 (95% CI: 5.83, 6.90) in the 25-34-year-old group. Conclusion: There are large age-group and regional differences in CHB prevalence in Turkey, where CHB remains a serious health problem.
AB - Background: To provide a clear picture of the current hepatitis B situation, the authors performed a systematic review to estimate the age-and region-specific prevalence of chronic hepatitis B (CHB) in Turkey. Methods: A total of 339 studies with original data on the prevalence of hepatitis B surface antigen (HBsAg) in Turkey and published between 1999 and 2009 were identified through a search of electronic databases, by reviewing citations, and by writing to authors. After a critical assessment, the authors included 129 studies, divided into categories: 'age-specific'; 'region-specific'; and 'specific population group'. To account for the differences among the studies, a generalized linear mixed model was used to estimate the overall prevalence across all age groups and regions. For specific population groups, the authors calculated the weighted mean prevalence. Results: The estimated overall population prevalence was 4.57, 95% confidence interval (CI): 3.58, 5.76, and the estimated total number of CHB cases was about 3.3 million. The outcomes of the age-specific groups varied from 2.84, (95% CI: 2.60, 3.10) for the 0-14-yearolds to 6.36 (95% CI: 5.83, 6.90) in the 25-34-year-old group. Conclusion: There are large age-group and regional differences in CHB prevalence in Turkey, where CHB remains a serious health problem.
U2 - 10.1186/1471-2334-11-337
DO - 10.1186/1471-2334-11-337
M3 - Article
VL - 11
JO - BMC Infectious Diseases
JF - BMC Infectious Diseases
SN - 1471-2334
ER -